Scandinavian Biopharma awarded the Swedish national tender for the TdaP booster vaccine

The national public tender for the booster dose of TdaP vaccine (diphtheria, tetanus and pertussis), has now been completed. Scandinavian Biopharma was for the second consecutive period awarded this tender and diTekiBooster will continue to be administered to all adolescents in Sweden 13-14 years old. diTekiBooster was considered to have a medical benefit due to its high content of pertussis toxoid. The new tender period will start September 1st 2019. The tender period is 2 years with the possibility to be prolonged another 2 years.



Go to MyNewsdesk

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.